Indicator 2 (breast cancer patients who had diagnosis in cytology and/or histology before surgery) showed the greatest difference (51.72%), followed by indicator 13 (proportion of breast cancer patients who received standard dose of radiotherapy at the whole breast after breast-conserving surgery) at 43.64%, indicator 15 (breast cancer patients who received tamoxifen or aromatase inhibitor treatment) at 42.84% and indicator 12 (treatment was completed within a 7-week interval from the initiation of radiotherapy after breast-conserving surgery) at 40.94%. The gene discussed is CYP19A1; the disease is breast carcinoma.